News and Trends 7 Dec 2022 FDA clears insulin pen medical device BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 23 Nov 2022 Novo Nordisk announces $750M facility expansion Novo Nordisk has announced plans to invest DKK 5.4 bn ($750m) in the expansion of existing facilities in Bagsværd, Denmark. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global […] November 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Nov 2022 Novo Nordisk supports Plant2Food platform with €27M funding Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 ASPIRE set up to collaborate on amyloidosis A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […] October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research The Novo Nordisk Foundation has awarded a grant of $200 million to establish the first full-scale quantum computer for the development of new medicines. The computer will also provide new insights into climate change and the green transition, which is not possible with classical computers today. The computer could be located in a data center, […] September 21, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 More companies enter BioInnovation Institute Venture Lab program Nine ventures and two projects have become the latest addition to The BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BioInnovation Institute is an international commercial non-profit foundation based in Denmark, which incubates and accelerates life science research. The cohort consists of nine ventures plus two corporate-sponsored innovation projects from Novo Nordisk – […] September 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2022 Report shows growth of life sciences sector in eastern Denmark A new report on the Danish contribution to the Medicon Valley has been published. The report, Life Science in Eastern Denmark – The Danish Part of Medicon Valley is a survey of companies in the sector. Medicon Valley spans the Danish region of Zealand and the Capital Region, and the Skåne region of southern Sweden. […] June 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2022 Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […] January 17, 2022 - 3 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2021 Novo Nordisk Foundation Pumps €85M into Carbon Capture Research As pressure mounts to tackle climate change, the Danish Novo Nordisk Foundation has granted €84.7M to the world’s first research institution dedicated to capturing carbon dioxide from the air and harnessing the gas as a raw material. The new Novo Nordisk Foundation CO2 Research Center has the mission to efficiently capture, store, and recycle the […] October 1, 2021 - 6 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […] June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2020 Novo Nordisk Foundation Commits €100M Grant to Developing Green Tech The Novo Nordisk Foundation has awarded a five-year grant of €100M to the DTU Biosustain research center near Copenhagen to support the development of sustainable green technology. DTU Biosustain was founded in 2011 and forms part of the Danish Technical University. The Novo Nordisk Foundation, which is one of the largest charitable foundations in the […] June 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2020 Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […] May 13, 2020 - 4 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email